Korean Circ J.  2013 Jul;43(7):462-467. 10.4070/kcj.2013.43.7.462.

The Impact of Trimetazidine Treatment on Left Ventricular Functions and Plasma Brain Natriuretic Peptide Levels in Patients with Non-ST Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

• Demirelli
• Karakelleoglu S
• Gundogdu F
• Tas MH
• Kaya A
• Duman H
• Degirmenci H
• Hamur H
• Simsek Z

• KMID: 2145501
• DOI: http://doi.org/10.4070/kcj.2013.43.7.462

Abstract

BACKGROUND AND OBJECTIVES
The aim of this study was to investigate the impact of treatment with oral trimetazidine (TMZ) applied before and after percutaneous coronary interventions (PCI) on short-term left ventricular functions and plasma brain natriuretic peptide (BNP) levels in patients with non-ST segment elevation myocardial infarction (NSTEMI) undergoing PCI.
SUBJECTS AND METHODS
The study included 45 patients who were undergoing PCI with the diagnosis of NSTEMI. The patients were randomized into two groups. The first group (n=22) of the patients hospitalized with the diagnosis of NSTEMI was given conventional therapy plus 60 mg TMZ just prior to PCI. Treatment with TMZ was continued for one month after the procedure. TMZ treatment was not given to the second group (n=23). Echocardiography images were recorded and plasma BNP levels were measured just prior to the PCI and on the 1st and 30th days after PCI.
RESULTS
The myocardial performance index (MPI) was greater in the second group (p=0.02). In the comparison of BNP levels, they significantly decreased in both of the groups during the 30-day follow-up period (29.0+/-8 and 50.6+/-33, p<0.01 respectively). However, decreasing of BNP levels was higher in the group administered with TMZ. The decrease of left ventriclular end-diastolic volume was observed in all groups at 30 days after intervention, but was higher in the group administered with TMZ (p=0.01).
CONCLUSION
Trimetazidine treatment commencing prior to PCI and continued after PCI in patients with NSTEMI provides improvements in MPI, left ventricular end diastolic volume and a decrease in BNP levels.

Keyword

Natriuretic peptide, brain; Percutaneous coronary intervention; Trimetazidine

MeSH Terms

Brain
Echocardiography
Follow-Up Studies
Humans
Myocardial Infarction
Natriuretic Peptide, Brain
Percutaneous Coronary Intervention
Plasma
Stroke Volume
Trimetazidine
Ventricular Function, Left
Natriuretic Peptide, Brain
Trimetazidine

Figure

• 

  Fig. 1 Changes in the left ventricular ejection fraction (LVEF), left ventricular end-disatolic volume (LVEDV), and plasma brain natriuretic peptide (BNP) levels during the follow-up period.

Reference

1. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001; 22:2267–2274.

2. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol. 1998; 30:A112.

3. Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol. 1993; 21:128–135.

4. American Heart Association. 1999 heart and stroke statistical update. Chicago: American Heart Association;1999.

5. Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. 2000; 342:1163–1170.

6. Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2006; 98:14J–18J.

7. Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol. 2007; 120:79–84.

8. Nakamura S, Naruse M, Naruse K, et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens. 1991; 4:909–912.

9. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993; 87:464–469.

10. White HD, French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2003; 42:1917–1920.

11. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40:437–445.

12. Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin. 2004; 20:1447–1454.

13. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000; 86:580–588.

14. Banach M. The role of trimetazidine in the treatment of heart diseases. Ponzan, Poland: Termedia Publishing House;2006. p. 52–56.

15. Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res. 2002; 45:69–72.

16. López N, Varo N, Díez J, Fortuño MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res. 2007; 75:536–545.

17. Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs. 2002; 11:615–629.

18. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006; 48:992–998.

19. Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs. 2007; 7:143–150.